Alpha-GPC (L-Alpha-Glycerylphosphorylcholine)
ألفا-GPC (إل-ألفا-غليسيريل فوسفوريل كولين)
Nootropic / choline form · CAS: 28319-77-9
Popular for focus - but ORIA is flagging it, and here's the honest why. Alpha-GPC delivers choline to the brain and is sold hard for memory, study focus and gym 'mind-muscle' performance. The trouble is the trade. In healthy people the brain benefit is small and inconsistent - most studies don't show much. Against that thin upside sits a heavyweight safety signal: a study following more than 12 million older adults found that alpha-GPC users had about a 46% higher risk of stroke over ten years, and the more they took, the higher the risk, with a believable biological explanation (choline can be turned by gut bacteria into TMAO, which damages arteries). This is an association, not a verdict - a later study was less clear-cut - but when the benefit is shaky and the possible downside is a stroke, a doctor's instinct is to be cautious, not casual. That's why ORIA marks this caution rather than okay. If you're older or have heart or stroke risk factors, this is one to discuss with your doctor before using.
Why this verdict
A choline-donor nootropic that crosses into the brain and raises acetylcholine. It is widely sold for memory, focus and athletic 'mind-muscle' performance, and has prescription/clinical use for cognitive decline in some countries. ORIA grades it CAUTION - a deliberate step below 'okay' - because the risk-benefit is unfavourable for the typical healthy user: the cognitive benefit in healthy people is weak and inconsistent, while a very large study raises a serious safety question. A South Korean national cohort of over 12 million adults aged 50+ found alpha-GPC use associated with a dose-responsive ~46% higher 10-year stroke risk, with a plausible mechanism (choline → gut-derived TMAO → atherosclerosis). The signal is observational, not proof, and a later analysis was more equivocal - but combined with thin efficacy, ORIA judges that an unproven benefit does not justify a possible stroke risk.
What It Is
Choline-donor nootropic (raises brain acetylcholine). Heavily marketed for focus/'mind-muscle'; benefit in healthy people weak/mixed. SAFETY SIGNAL: 12M-person Korean cohort = dose-responsive ~46% higher 10-yr stroke risk (choline→TMAO mechanism); observational, later debated. Unproven benefit + serious harm signal → ORIA grades CAUTION. Discuss with doctor if CV/stroke risk.
Alpha-GPC (L-alpha-glycerylphosphorylcholine, or choline alphoscerate) is a choline-rich compound that crosses the blood-brain barrier and raises brain levels of acetylcholine, the neurotransmitter central to memory and attention. On that mechanism it has been built into a popular nootropic and pre-workout ingredient, promoted for studying, focus and the 'mind-muscle connection,' and in several countries it is even a prescription treatment for cognitive decline. ORIA nonetheless places it at caution - one notch below okay - and the reasoning is a deliberate risk-benefit weighing rather than any single scary fact. On the benefit side, the evidence is underwhelming for the healthy people who mostly buy it: the better-quality data sit in Alzheimer's and clinical populations, while studies in healthy adults are small, few and inconsistent, with most failing to demonstrate a clear cognitive gain. On the risk side sits an unusually large signal. A population study using South Korea's national health database followed more than 12 million adults aged 50 and over and found that alpha-GPC users had a dose-responsive increase in 10-year stroke risk - roughly 46% higher overall - even after adjusting for traditional cardiovascular risk factors. There is a coherent mechanism: choline can be converted by gut microbes into trimethylamine-N-oxide (TMAO), a metabolite linked to atherosclerosis. Honesty requires noting the limits: this is an observational association, not proof of cause, the study comes from a single country's records, and a subsequent cohort in people with mild cognitive impairment found no significant stroke difference after careful matching - so the question is genuinely unsettled. But ORIA's job is to weigh facts the way a careful physician would, and when a supplement's benefit for a healthy person is weak and the unresolved downside is stroke, 'proceed with caution' is the honest call, not 'this is fine.' Anyone older or carrying cardiovascular or cerebrovascular risk should specifically discuss alpha-GPC with their doctor before taking it. Verdict: a heavily-marketed focus aid whose modest, shaky upside does not clearly outweigh a serious safety question - caution.
Evidence & Status
EU Status
Permitted as food supplement / sold as choline alphoscerate; a prescription cognitive treatment in some EU countries.
US · FDA Status
Sold as a dietary supplement (GRAS-classified ingredient).
Intake & Safety
Upper limit (UL)
No alpha-GPC-specific UL; choline UL 3,500 mg/day (adults)
Interactions
Caution in people with elevated cardiovascular/stroke risk (observational stroke association). Additive cholinergic effects with cholinergic agents/cholinesterase inhibitors; theoretical interaction with anticholinergics.
Third-party testing
useful (purity/identity; reputable manufacturer - but cert does not offset the stroke-risk question)
Halal Status: Source dependent
Typically derived from soy or sunflower lecithin (plant) → generally permissible; check capsule/softgel shell.
Standard: Lecithin-derived (usually plant) — generally permissible; confirm softgel shell per MS 1500:2019.
Worth Knowing
Also Known As
alpha-GPC · α-GPC · choline alphoscerate · glycerophosphocholine · GPC · ألفا جي بي سي · كولين ألفوسيرات
Primary Source
Evidence, not medical advice. You decide.
More In This Category
Get ORIA when it launches
Join the waitlist - we'll email you the moment ORIA lands. Then scan any product and get a clear verdict on every ingredient, in seconds.
Coming soon to iOS and Android